Xilio Therapeutics Inc (XLO)

Apr 23, 2025, 4:30 PM EDT - 3 days ago

Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting

Apr 4, 2025, 4:30 PM EDT - 22 days ago

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 11, 2025, 7:30 AM EDT - 6 weeks ago

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Feb 24, 2025, 4:30 PM EST - 2 months ago

Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Feb 12, 2025, 10:44 AM EST - 2 months ago

Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday?

Feb 12, 2025, 7:35 AM EST - 2 months ago

Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

Feb 12, 2025, 7:33 AM EST - 2 months ago

AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

Jan 21, 2025, 5:05 PM EST - 3 months ago

Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

Jan 17, 2025, 4:30 PM EST - 3 months ago

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 19, 2024, 7:30 AM EST - 4 months ago

Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI

Dec 16, 2024, 7:30 AM EST - 4 months ago

Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer

Dec 3, 2024, 4:30 PM EST - 5 months ago

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 7, 2024, 9:15 AM EST - 6 months ago

Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors

Nov 7, 2024, 9:05 AM EST - 6 months ago

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results

Oct 30, 2024, 9:01 AM EDT - 6 months ago

Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Oct 4, 2024, 9:05 AM EDT - 7 months ago

Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Aug 28, 2024, 4:01 PM EDT - 8 months ago

Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 8, 2024, 7:30 AM EDT - 9 months ago

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results

Jun 13, 2024, 4:05 PM EDT - 11 months ago

Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D.

May 14, 2024, 7:30 AM EDT - 1 year ago

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results

Apr 1, 2024, 4:05 PM EDT - 1 year ago

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results

Mar 28, 2024, 7:05 AM EDT - 1 year ago

Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing

Mar 28, 2024, 7:00 AM EDT - 1 year ago

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

GILD

Feb 28, 2024, 4:01 PM EST - 1 year ago

Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference

Jan 31, 2024, 4:01 PM EST - 1 year ago

Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference

Jan 8, 2024, 7:30 AM EST - 1 year ago

Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies

Dec 7, 2023, 7:30 AM EST - 1 year ago

Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data

Nov 9, 2023, 4:01 PM EST - 1 year ago

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results

Nov 3, 2023, 12:00 PM EDT - 1 year ago

Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors

Oct 31, 2023, 9:15 AM EDT - 1 year ago

Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting

Sep 27, 2023, 5:02 PM EDT - 1 year ago

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 5, 2023, 8:30 AM EDT - 1 year ago

Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D.

Sep 5, 2023, 7:30 AM EDT - 1 year ago

Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference

Aug 14, 2023, 7:30 AM EDT - 1 year ago

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results

Aug 3, 2023, 4:05 PM EDT - 1 year ago

Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer

May 25, 2023, 5:01 PM EDT - 2 years ago

Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors

May 9, 2023, 7:30 AM EDT - 2 years ago

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results

Mar 2, 2023, 4:05 PM EST - 2 years ago

Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results

Feb 27, 2023, 7:30 AM EST - 2 years ago

Xilio Therapeutics to Present at Upcoming Investor Conferences

Feb 16, 2023, 7:30 AM EST - 2 years ago

Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit

Feb 2, 2023, 7:30 AM EST - 2 years ago

Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day

Nov 23, 2022, 7:30 AM EST - 2 years ago

Xilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12

Nov 9, 2022, 7:30 AM EST - 2 years ago

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results

Nov 4, 2022, 7:30 AM EDT - 2 years ago

Xilio Therapeutics to Present at Cowen 6th Annual ‘IO Next' Summit

Sep 22, 2022, 4:05 PM EDT - 2 years ago

Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference

Sep 15, 2022, 4:05 PM EDT - 2 years ago

Xilio Therapeutics Appoints Tomas J. Heyman to Board of Directors

Sep 6, 2022, 4:05 PM EDT - 2 years ago

Xilio Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference

Aug 9, 2022, 7:30 AM EDT - 2 years ago

Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial Results

Jun 16, 2022, 7:30 AM EDT - 3 years ago

Xilio Therapeutics Announces Promotion of Martin Huber, M.D., to President

May 18, 2022, 7:30 AM EDT - 3 years ago

Xilio Therapeutics to Present at the H.C. Wainwright Global Investment Conference